GC Biopharma's Hunterase ICV Approved as First Domestic Treatment for Neuronopathic Hunter Syndrome
Predicted impact: Low
Domestic approval of Hunterase ICV, already reported in the last 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.